Peregrine Pharmaceuticals Reports Financial Results for First Quarter of Fiscal Year 2018 and Recent Developments
11. September 2017 16:05 ET
|
Peregrine Pharmaceuticals Inc.
-- Avid Bioservices Records Revenues of $27 Million in the First Quarter of FY2018 -- -- Roger Lias, Ph.D., Appointed President of Avid Bioservices as Company Continues Transition to a...
Peregrine Pharmaceuticals Announces Appointment of Roger J. Lias, Ph.D. as President of Avid Bioservices
11. September 2017 08:05 ET
|
Peregrine Pharmaceuticals Inc.
TUSTIN, Calif., Sept. 11, 2017 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a biopharmaceutical company committed to improving patient lives by manufacturing...
Peregrine Pharmaceuticals Announces First Patient Dosed in Phase II Clinical Trial Evaluating Bavituximab Treatment Combination in Patients with Newly Diagnosed Glioblastoma
07. September 2017 08:10 ET
|
Peregrine Pharmaceuticals Inc.
TUSTIN, Calif., Sept. 07, 2017 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a biopharmaceutical company committed to improving patient lives by manufacturing...
Peregrine to Report Financial Results for First Quarter of Fiscal Year 2018 After Market Close on September 11, 2017
06. September 2017 16:05 ET
|
Peregrine Pharmaceuticals Inc.
TUSTIN, Calif., Sept. 06, 2017 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a biopharmaceutical company committed to improving patient lives by manufacturing...
Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock
05. September 2017 16:05 ET
|
Peregrine Pharmaceuticals Inc.
TUSTIN, Calif., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (Nasdaq:PPHM) (Nasdaq:PPHMP) today announced that its Board of Directors has declared a quarterly cash dividend...
Peregrine Announces Measures to Reduce Costs, Facilitate Profitability and Strengthen its Operations
11. August 2017 08:30 ET
|
Peregrine Pharmaceuticals Inc.
Reductions in R&D, manufacturing and administrative personnel Anticipated annual cost savings of over $7 million TUSTIN, Calif., Aug. 11, 2017 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals,...
Peregrine Provides Strategic Update
31. Juli 2017 08:30 ET
|
Peregrine Pharmaceuticals Inc.
Plans to Expand Board of Directors to Add CDMO and Biologics Industry Expertise Search for a Dedicated President to Head Avid Bioservices CDMO Business to Commence Continues to Evaluate Strategic...
Peregrine Pharmaceuticals Reports Financial Results for Quarter and Fiscal Year Ended April 30, 2017 and Recent Developments
14. Juli 2017 16:13 ET
|
Peregrine Pharmaceuticals Inc.
-- Avid Achieves Year-Over-Year Topline Revenue Growth of 30% Exceeding $57 Million -- -- Recent Presentation Supports Bavituximab’s Potential to Improve Clinical Outcome for Immune Checkpoint...
Peregrine Pharmaceuticals Issues Statement Regarding Ronin Trading and SW Investment Management’s Letter to Stockholders
13. Juli 2017 18:08 ET
|
Peregrine Pharmaceuticals Inc.
TUSTIN, Calif., July 13, 2017 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) today confirmed that Ronin Trading, LLC and SW Investment Management LLC (together, “Ronin/SWIM”)...
Peregrine to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2017 After Market Close on July 14, 2017
07. Juli 2017 16:05 ET
|
Peregrine Pharmaceuticals Inc.
TUSTIN, Calif., July 07, 2017 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a biopharmaceutical company committed to improving patient lives by manufacturing high...